Clinical investigator costs are one of the largest budget items in the entire research and development process. Results of a recent study on pharmaceutical company payment practices and clinical investigator grant payments collected as part of the ongoing Pharmaceutical Investigator Costs Analysis Service (PICAS) database project are interpreted and discussed. This information is vital in light of the new cost control environment.
